ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2444

Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation

(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2170

I Know It When I See It! Improving Visual Diagnosis Education in Rheumatology Fellowship Training

(2159–2194) Professional Education Poster

10:30AM-12:30PM: Abstract Number: 2399

Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2140

Identification of immune phenotypes in systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD) using high parameter flow cytometry

(2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1985

Identifying Gaps in Documented Contraception Counseling and Gynecology Referrals for Women on Teratogenic DMARDs: A Foundation for EMR-Based Quality Improvement

(1972–1989) Measures & Measurement of Healthcare Quality Poster II

10:30AM-12:30PM: Abstract Number: 2529

IgG4-Related Disease Paravertebral and Ureteropelvic Mass Presentations are Linked to Specific Disease Features

(2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: Abstract Number: 2495

IL-6/STAT3 Signaling is Central for Chemokine Production in E2-Induced Dermal Inflammation

(2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1962

Imaging findings in patients with enteropathic spondyloarthritis

(1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: Abstract Number: 2464

IMC-002 (IMM0306), a First-in-Class Bi-specific Fusion Protein, Demonstrates Improvements in Systemic Lupus Erythematosus (SLE) Disease Activity Measures and Biomarkers in Patients with Moderate to Severe Active SLE in the Open-label Phase 1b/2 Study

(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1845

Immune Cell Profiles and Transcriptomic Signatures of Atherosclerosis in Systemic Lupus Erythemathosus

(1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2062

Immune Cell Signatures Associated with Disease Activity in Dermatomyositis Across Autoantibody Subtypes

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2410

Immune Cell/Pathway-Specific Polygenic Risk Scores Reveal Immune Pathway Associations in Childhood-Onset Lupus Nephritis

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2277

Immunophenotyping of peripheral blood mononuclear cells reveals potential cellular biomarkers of disease in rheumatoid arthritis

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2146

Impact of a Clinical Pathway on Medication Use and Outcomes in Kawasaki Disease

(2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2510

Impact of ANCA specificity on risk of severe infection occurrence in ANCA-associated vasculitis.

(2504–2523) Vasculitis – ANCA-Associated Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].